NCT05886868 - Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

February 28, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

BL0020

"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."

Trial Locations (4)

Unknown

ACTIVE_NOT_RECRUITING

Cancer Care Foundation Limited, Sydney

RECRUITING

Scientia Clinical Research, Sydney

ACTIVE_NOT_RECRUITING

Sunshine Coast University Private Hospital, Birtinya

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Shanghai Best-Link Bioscience, LLC

INDUSTRY